Vestasync

VESTAsync is a polymer-free drug-eluting stent (DES) developed for the treatment of coronary artery disease. It features a nanometer-thin coating of hydroxyapatite (HA), a biocompatible mineral found in human bone, which serves as a reservoir for the anti-proliferative drug sirolimus (55 µg). The device is designed to address the inflammatory issues associated with permanent polymer coatings used in traditional DES. By releasing sirolimus, the stent inhibits neointimal hyperplasia, the primary cause of restenosis after angioplasty. Clinical trials, including VESTASYNC I and II, showed promising safety and efficacy, with low late lumen loss and no major adverse cardiac events (MACE) reported in early follow-ups. The hydroxyapatite coating is designed to be stable for approximately four months and completely dissolve after nine months, leaving behind a bare metal stent surface.

Brand names

VESTAsync

Other names

VESTAsync drug-eluting stent